Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lomustine
Drug ID BADD_D01313
Description An alkylating agent of value against both hematologic malignancies and solid tumors.
Indications and Usage For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
Marketing Status approved; investigational
ATC Code L01AD02
DrugBank ID DB01206
KEGG ID D00363
MeSH ID D008130
PubChem ID 3950
TTD Drug ID D04JPJ
NDC Product Code 55111-965; 58181-3041; 58181-3040; 58181-3042; 71052-171
UNII 7BRF0Z81KG
Synonyms Lomustine | NSC-79037 | NSC 79037 | NSC79037 | Cecenu | CeeNU | Belustine | CCNU
Chemical Information
Molecular Formula C9H16ClN3O2
CAS Registry Number 13010-47-4
SMILES C1CCC(CC1)NC(=O)N(CCCl)N=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neutropenia01.02.03.0040.000392%-
Optic atrophy06.09.02.001---
Osteoarthritis15.01.04.001---
Pancytopenia01.03.03.0030.000168%-
Paraesthesia17.02.06.005; 23.03.03.0940.000437%
Pulmonary fibrosis22.01.02.006--
Pyrexia08.05.02.0030.000112%
Renal failure20.01.03.005---
Seizure17.12.03.0010.000963%
Stomatitis07.05.06.005--
Thrombocytopenia01.08.01.0020.000694%-
Thrombosis24.01.01.0060.000168%-
Thrombotic microangiopathy01.01.02.006; 20.01.07.004; 24.01.01.0130.000112%-
Visual impairment06.02.10.013---
Vomiting07.01.07.0030.000548%
Contusion12.01.06.001; 15.03.05.007; 23.03.11.002; 24.07.06.001--
Transaminases increased13.03.04.036---
Haemorrhage24.07.01.002---
Dysplasia08.03.04.007---
Gastrointestinal toxicity07.08.03.006; 12.03.01.019---
Blood alkaline phosphatase increased13.04.02.004--
Neurological symptom17.02.05.010---
Haematotoxicity01.05.01.007; 12.03.01.0250.000280%-
Neoplasm progression16.16.02.0050.000246%-
Decreased appetite08.01.09.028; 14.03.01.005--
Renal injury12.01.05.001; 20.01.03.015---
Disease progression08.01.03.0380.001119%
Pulmonary toxicity12.03.01.013; 22.01.02.007---
Bone marrow failure01.03.03.005--
Oropharyngeal discomfort07.05.05.008; 22.12.03.015---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages